vtx958
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Nov 17, 2022 (NCT05655299)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Tyrosine-protein kinase TYK2INHIBITOR
TYK2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05715125 | Phase 2 | Jan 31, 2023 | Ventyx Biosciences, Inc. |
| NCT05688852 | Phase 2 | Dec 22, 2022 | Ventyx Biosciences, Inc. |
| NCT05655299 | Phase 2 | Nov 17, 2022 | Ventyx Biosciences, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ventyx Biosciences, Inc. | For profit | 3 | 3 | 1 | 2022 |
1 organizations
Page 1 / 1